查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1995520

RNA分析/轉錄組學市場：依產品、技術和應用分類－2026-2032年全球市場預測

RNA Analysis/Transcriptomics Market by Product, Technology, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計 RNA 分析/轉錄組學市場在 2025 年的價值為 65.7 億美元，在 2026 年成長至 72.8 億美元，到 2032 年達到 144.6 億美元，複合年成長率為 11.93%。

主要市場統計數據
基準年 2025 65.7億美元
預計年份：2026年 72.8億美元
預測年份 2032 144.6億美元
複合年成長率 (%) 11.93%

全面介紹正在重塑研究和臨床環境中 RNA 分析和轉錄組學的科學、操作和轉化因素。

RNA分析和轉錄組學領域正處於關鍵的轉折點，分子生物學、定序技術和計算分析的進步正在重新定義實驗和臨床方法。近年來，研究界已不再局限於簡單的基因表現簡介，而是採用高解析度、擴充性的方法，以捕捉細胞異質性、時間動態和複雜的調控機制。因此，研究重點已從基礎發現轉向轉化應用，為藥物研發、診斷和精密農業提供資訊。為此，研究機構和商業實驗室目前正優先考慮整合工作流程，以縮短從樣本到獲得結果的時間，同時提高可重複性和資料互通性。

高通量定序、單細胞技術創新和軟體主導生態系統的融合如何重新定義轉錄組學的營運重點和經營模式。

轉錄組學領域正經歷著一場變革性的轉變，這反映了技術的成熟和終端使用者需求的改變。在技​​術層面，定序通量的提高和單一樣本處理時間的縮短促使單細胞方法和高內涵批量分析得到更廣泛的應用，從而推動實驗室重新設計實驗，以更深入、更詳細地闡明生物系統。同時，數位PCR和改進的即時PCR方法持續為標靶檢測提供快速、高靈敏度的選擇，支援那些需要定量精度而非全基因組覆蓋範圍的診斷和檢驗工作流程。

評估近期美國關稅措施對全球轉錄組學採購、供應韌性和平台選擇的累積營運和策略影響。

美國近期貿易政策的變化和關稅措施導致全球實驗室設備、試劑及相關RNA分析組件的供應鏈進行調整。依賴跨境採購的企業和機構正在轉變籌資策略，導致供應商合格流程延長，庫存彈性也受到更多重視。關稅帶來的成本壓力促使製造商評估替代供應商、實現特定生產過程的本地化，並重新談判供應商契約，以維持利潤率並確保供應的連續性。

詳細的細分分析解釋了整個轉錄組學工作流程中不同的產品、技術和應用路徑如何產生差異化的需求訊號和研發重點。

精細化的細分觀點揭示了RNA分析領域不同產品、技術和應用的需求促進因素和推廣障礙。從產品類型來看，耗材和試劑的持續需求支撐著實驗室的連續性，對於需要批次間性能一致性和可靠供應的終端用戶而言，這是營運中的首要任務。儀器設備仍然是資本配置決策的關鍵，因為平台選擇決定了通量、檢測相容性和下游資料特徵。配套的軟體和服務如同“連接組織”，將原始數據轉化為可操作的洞察，並支援可擴展的分析，從而實現標準化、法規遵循和多中心協作。

決定全球轉錄組學應用路徑、夥伴關係策略和監管合規性的區域趨勢和基礎設施現狀。

區域趨勢反映了研究經費、監管環境、產業合作和臨床基礎設施的差異，進而影響轉錄組學工具和服務的採用、支持和商業化。在美洲，由學術機構、生物技術公司和臨床檢查室組成的緊密生態系統正在推動先進定序平台和單細胞技術的早期應用，這體現了轉化研究與商業性創新之間的緊密聯繫。這種環境孕育了一個競爭激烈的服務供應商產業，支援快速技術檢驗、策略合作以及從發現到臨床級檢測的規模化應用。

在轉錄組學領域中，解決方案供應商之間的競爭行為、整合策略和能力優先順序決定了供應商的選擇和合作機會。

RNA分析和轉錄組學價值鏈中各公司的活動呈現出技術差異化、服務拓展和策略整合的融合趨勢。儀器製造商持續在處理能力、準確性和易用性方面展開競爭，而試劑供應商則專注於穩健的化學性質、批間一致性以及能夠降低檢驗變異性的已驗證工作流程。同時，分析服務供應商和軟體供應商正在加速投資於雲端原生平台、標準化流程和解讀層，以滿足研究和臨床報告的需求。

領導者面臨的可操作的策略挑戰，以建立具有韌性的供應鏈、可互通的生態系統和臨床適用的轉錄組學解決方案。

產業領導者應採取積極主動的方式，強調其所有產品和營運組合的韌性、互通性和轉化應用能力。首先，組織藍圖應優先考慮濕實驗室團隊、生物資訊部門和採購部門之間的跨職能協作，以確保平台選擇既能帶來即時的實驗效益，又能實現長期的擴充性。投資決策應優先考慮模組化解決方案，以便在不犧牲檢驗性能的前提下逐步擴展產能，並最大限度地減少對專有組件的依賴。

採用穩健的混合方法研究設計，結合相關人員訪談、技術基準測試和情境分析，以確保為轉錄組學相關人員。

本研究整合了關鍵相關人員的意見、技術文獻和檢驗的技術評估，對RNA分析和轉錄組學的發展趨勢進行了全面、基於證據的分析。主要數據透過對實驗室負責人、採購負責人和技術開發人員的結構化訪談收集，並輔以記錄檢測性能和可重複性的供應商藍圖以及同行評審的方法學研究。二級資訊來源包括說明工作流程效率和檢驗要求的技術白皮書、監管指導文件和基準研究。

整合策略重點，突顯技術能力、運作韌性和轉錄組學轉化研究準備之間的相互作用。

總之，RNA分析和轉錄組學正從探索性科學轉向一個綜合領域，技術選擇、資料管理和供應鏈韌性共同決定研究和轉化成果的成敗。單細胞定序和高通量定序的進步正在帶來新的生物學見解，但其潛力取決於嚴謹的工作流程、可互通的分析以及可靠的試劑和服務生態系統。對於尋求永續生產力的機構而言，營運韌性（包括多樣化的資源取得、清晰的供應商支援和檢驗的通訊協定）與技術能力同等重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 RNA分析/轉錄組學市場：依產品分類

  • 耗材和試劑
  • 裝置
  • 軟體服務

第9章 RNA分析/轉錄組學市場：依技術分類

  • 數位PCR
  • 微陣列
  • 次世代定序
    • 批量轉錄組學
    • 單細胞轉錄組學
      • 基於液滴的
      • 基於微流體技術的
  • 即時PCR

第10章 RNA分析/轉錄組學市場：依應用分類

  • 癌症研究
  • 藥物發現
  • 基因檢測
    • 攜帶者篩檢
    • 疾病診斷
    • 產前和新生兒篩檢
  • 感染疾病調查
  • 工廠調查

第11章 RNA分析/轉錄組學市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 RNA分析/轉錄組學市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 RNA分析/轉錄組學市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國RNA分析/轉錄組學市場

第15章：中國RNA分析/轉錄組學市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Illumina, Inc.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Roche Diagnostics International AG
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
  • Zymo Research Corporation
Product Code: MRR-FB6C9E7932C7

The RNA Analysis/Transcriptomics Market was valued at USD 6.57 billion in 2025 and is projected to grow to USD 7.28 billion in 2026, with a CAGR of 11.93%, reaching USD 14.46 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.57 billion
Estimated Year [2026] USD 7.28 billion
Forecast Year [2032] USD 14.46 billion
CAGR (%) 11.93%

A comprehensive primer on the scientific, operational, and translational forces reshaping RNA analysis and transcriptomics across research and clinical domains

The field of RNA analysis and transcriptomics is at a pivotal juncture, driven by advances in molecular biology, sequencing technologies, and computational analytics that together are redefining experimental and clinical approaches. Over the past several years, the community has moved beyond simple gene expression snapshots to adopt high-resolution, scalable methods that capture cellular heterogeneity, temporal dynamics, and regulatory complexity. As a result, research priorities have expanded from foundational discovery to translational applications that inform drug development, diagnostics, and precision agriculture. Consequently, institutions and commercial laboratories now prioritize integrated workflows that reduce time from sample to insight while increasing reproducibility and data interoperability.

Given these dynamics, laboratory leaders and strategic planners must balance investments across recurring consumables, capital instrumentation, and software-enabled analytics. Operational decisions increasingly hinge on the ability to harmonize wet-lab protocols with robust bioinformatics pipelines, including cloud-native solutions that support large-scale transcriptomics datasets. Moreover, stakeholder expectations have shifted: funders and regulators demand transparent validation, clinical partners need standardized assays, and publishing outlets require comprehensive metadata and reproducible pipelines. In sum, the RNA analysis landscape now rewards organizations that combine technological excellence with operational rigor, comprehensive data stewardship, and clear translational roadmaps that bridge discovery and application.

How converging high-throughput sequencing, single-cell innovations, and software-driven ecosystems are redefining operational priorities and commercial models in transcriptomics

The landscape of transcriptomics is undergoing transformative shifts that reflect both technological maturation and changing end-user requirements. Technologically, improvements in sequencing throughput and reductions in per-sample processing times have enabled broader adoption of single-cell approaches and high-content bulk studies, prompting laboratories to rethink experimental design toward deeper, more granular interrogation of biological systems. Concurrently, digital PCR and refined real-time PCR methods continue to provide rapid, high-sensitivity options for targeted assays, supporting diagnostics and validation workflows that require quantitative precision rather than genome-scale breadth.

Equally important is the convergence of laboratory automation, novel microfluidic platforms, and machine learning-driven analytics, which together permit higher throughput and more reproducible data generation. This integration is shifting value from standalone instruments to coupled ecosystems where consumables, instrument firmware, and analytical software are co-optimized. Business models are adapting in response: subscription and service-centric approaches for software and cloud analytics are becoming more prominent, while manufacturers emphasize validated end-to-end solutions for clinical and regulated environments. Additionally, as collaborative networks and multi-site studies grow, standards for data exchange, quality control, and assay validation are becoming more consequential, fostering an environment where interoperability and compliance are critical competitive differentiators.

Assessing the cumulative operational and strategic consequences of recent United States tariff actions on global procurement, supply resilience, and platform selection in transcriptomics

Recent trade policy developments and tariff actions in the United States have created a recalibration across global supply chains for laboratory equipment, reagents, and related components that support RNA analysis. Companies and institutions reliant on cross-border sourcing have experienced shifts in procurement strategies, prompting extended supplier qualification processes and increased emphasis on inventory resilience. Tariff-related cost pressures have incentivized manufacturers to evaluate alternative sourcing, localize certain production steps, and renegotiate supplier contracts to preserve margin and ensure continuity of supply.

Operationally, these changes have manifested as elongated lead times for specific instrument components and specialized reagents, with procurement teams instituting contingency inventories and diversified vendor lists to mitigate disruption. Research groups have adjusted procurement cadence and, in some cases, selected platforms with broader local service footprints to reduce exposure to import-related delays. From a product-development perspective, firms are accelerating design for manufacturability initiatives that reduce reliance on geopolitically sensitive parts and that enable modular sourcing across multiple regions.

Furthermore, the cumulative effect of tariff measures has driven strategic partnerships between suppliers and distributors to smooth customs compliance and to streamline logistics. These collaborations often include co-investment in regional warehousing, harmonized documentation processes, and expanded field service networks. For translational research and clinical assay deployment, the net impact includes a greater emphasis on supply-chain transparency, vendor management, and contractual safeguards that align procurement with operational risk tolerance. Looking forward, stakeholders are likely to continue prioritizing resilience and flexibility in sourcing decisions while monitoring policy shifts that could alter cross-border trade dynamics for critical laboratory inputs.

Deep segmentation analysis explaining how distinct product, technology, and application pathways create differentiated demand signals and R&D priorities across transcriptomics workflows

A granular segmentation perspective reveals differentiated demand drivers and adoption barriers across products, technologies, and applications in RNA analysis. When viewed by product type, recurring demand for consumables and reagents underpins laboratory continuity and represents a central operational priority for end users who require consistent lot-to-lot performance and supply reliability. Instruments remain a critical focal point for capital allocation decisions because platform selection dictates throughput, assay compatibility, and downstream data characteristics. Complementary software and services form the connective tissue that converts raw measurements into actionable knowledge, enabling standardization, regulatory compliance, and scalable analytics for multi-site studies.

By technology, the ecosystem includes digital PCR and real-time PCR as robust tools for targeted quantification and validation, while microarray technologies retain a niche for specific comparative expression studies. Next Generation Sequencing has emerged as the dominant high-resolution approach, with bulk transcriptomics serving broad discovery use cases and single cell transcriptomics enabling interrogation of heterogeneous tissues and rare cell types. Within single-cell studies, droplet-based methods provide high-throughput cell partitioning suitable for large-scale atlasing projects, whereas microfluidics-based platforms offer precise control for specialized assays and multiomic integrations. Each technological class carries distinct workflow implications: sample preparation requirements, computational needs, and quality control benchmarks vary and therefore influence adoption curves across organizations.

Application-driven segmentation further clarifies prioritization. Cancer research continues to demand deep transcriptomic profiling to elucidate tumor heterogeneity and therapeutic resistance mechanisms, while drug discovery leverages expression signatures and pathway analyses for target identification and pharmacodynamics. Genetic testing programs require robust, validated assays across carrier screening, disease diagnostics, and prenatal and newborn applications, with particular emphasis on assay sensitivity, specificity, and regulatory readiness. Infectious disease research relies on rapid, high-sensitivity assays and scalable sequencing to track pathogens and host responses, and plant research increasingly adopts transcriptomic tools to accelerate trait discovery and stress-response characterization. Understanding these intersecting segmentation axes helps organizations align product portfolios, R&D investments, and commercial strategies to the nuanced needs of each user community.

Regional dynamics and infrastructure realities that determine adoption pathways, partnership strategies, and regulatory alignment for transcriptomics across global geographies

Regional dynamics shape how transcriptomics tools and services are adopted, supported, and commercialized, reflecting differences in research funding, regulatory landscapes, industrial partnerships, and clinical infrastructure. In the Americas, a dense ecosystem of academic centers, biotech companies, and clinical laboratories drives early adoption of advanced sequencing platforms and single-cell technologies, with strong ties between translational research and commercial innovation. This environment fosters rapid technology validation, strategic collaborations, and a competitive service-provider sector that supports scaling from discovery to clinical-grade assays.

Across Europe, the Middle East, and Africa, adoption patterns are heterogeneous: leading research hubs and national initiatives accelerate uptake of high-throughput platforms and standardized workflows, while broader regional disparities reflect variable access to capital and laboratory infrastructure. Regulatory frameworks in some European jurisdictions place particular emphasis on clinical validation and data privacy, prompting suppliers to emphasize compliance and localized support. Meanwhile, collaborative consortia and pan-regional projects help disseminate best practices and enable resource-sharing for high-cost technologies.

In the Asia-Pacific region, expanding public and private investment in life sciences has elevated demand for both instruments and consumables. Several countries are developing strong domestic manufacturing and service capabilities, which influences procurement preferences and price sensitivity. Rapidly growing research communities and clinical genomics programs are driving adoption across pharmaceutical, agricultural, and public health domains. Taken together, these regional dynamics necessitate differentiated commercial strategies: multinational suppliers must tailor go-to-market approaches, service models, and partnerships to align with local regulatory requirements, infrastructure maturity, and customer support expectations.

Competitive behaviors, integration strategies, and capability priorities among solution providers that determine vendor selection and partnership opportunities in transcriptomics

Company activity across the RNA analysis and transcriptomics value chain reflects a blend of technological differentiation, service expansion, and strategic consolidation. Instrument manufacturers continue to compete on throughput, accuracy, and ease of use, while reagent suppliers focus on robust chemistry, lot consistency, and validated workflows that reduce assay variability. At the same time, analytics providers and software vendors are accelerating investments in cloud-native platforms, standardized pipelines, and interpretive layers that address both research and clinical reporting needs.

Strategic behaviors include targeted M&A to secure proprietary chemistries or analytics assets, partnership-based go-to-market approaches that bundle instruments with consumables and data services, and expanded field service networks to support global deployment. Companies that successfully integrate hardware, chemistry, and software often gain a competitive edge by reducing end-user validation burden and enabling faster time to insight. Conversely, specialist providers that focus on niche assay chemistries, microfluidic innovations, or advanced bioinformatics can capture value through collaborations with platform vendors and contract research organizations.

For customers, vendor selection now involves assessment of long-term support, interoperability, and the breadth of validated applications. Procurement decisions increasingly weigh roadmap transparency, regulatory readiness, and the availability of training and application support. The evolving competitive landscape favors organizations that can demonstrate demonstrable reproducibility, comprehensive validation datasets, and pragmatic pathways for clinical translation or industrial scale-up.

Actionable strategic imperatives for leaders to build resilient supply chains, interoperable ecosystems, and clinically translatable transcriptomics offerings

Industry leaders should adopt a proactive stance that emphasizes resilience, interoperability, and translational readiness across product and operational portfolios. First, organizational roadmaps must prioritize cross-functional alignment between wet-lab teams, bioinformatics units, and procurement to ensure that platform selections deliver both immediate experimental benefits and long-term scalability. Investment decisions should favor modular solutions that allow incremental expansion of capacity and that minimize lock-in to proprietary components without sacrificing validated performance.

Second, firms should double down on supply-chain transparency and diversified sourcing to mitigate geopolitical and tariff-related risks. This includes qualifying alternative suppliers, securing strategic inventory buffers for critical reagents, and negotiating service-level agreements that provide clarity on lead times and support. Third, vendors and service providers should emphasize open standards, common data formats, and validated APIs to facilitate interoperability across instruments, LIMS, and analytics platforms, reducing integration overhead for end users.

Fourth, commercial teams should structure offerings around outcome-focused value propositions that combine instrumentation, validated consumables, and analytics services. For translational initiatives, companies must build or partner for robust clinical validation pathways, regulatory expertise, and reproducible documentation that meet certification requirements. Finally, leaders should invest in workforce enablement-training programs, methodological workshops, and application support-to ensure that customers realize the full potential of transcriptomics technologies while maintaining high standards of data quality and assay reproducibility.

Robust mixed-methods research design combining stakeholder interviews, technical benchmarking, and scenario analyses to ensure reproducible and actionable insights for transcriptomics stakeholders

This research synthesized primary stakeholder input, technical literature, and validated technology assessments to produce a comprehensive, evidence-based analysis of RNA analysis and transcriptomics trends. Primary data were gathered through structured interviews with laboratory directors, procurement specialists, and technology developers, complemented by vendor roadmaps and peer-reviewed methodological studies that document assay performance and reproducibility. Secondary sources included technical white papers, regulatory guidance documents, and benchmarking studies that describe workflow efficiencies and validation requirements.

Analytical methods combined qualitative thematic coding of stakeholder interviews with comparative technology profiling and scenario-based supply-chain analysis. Key performance attributes-such as assay sensitivity, throughput, workflow complexity, and computational requirements-were mapped across product and technology segments to highlight compatibility constraints and enabling capabilities. Where appropriate, case examples and real-world operational practices were used to illustrate how institutions navigate platform selection and deployment. Throughout the process, findings were cross-validated via expert review cycles to ensure technical accuracy and practical relevance for both research and clinical audiences.

Synthesis of strategic priorities highlighting the interplay of technological capability, operational resilience, and translational readiness in transcriptomics

In conclusion, RNA analysis and transcriptomics are transitioning from exploratory science to an integrated field where technological selection, data stewardship, and supply-chain resilience jointly determine research and translational success. Advances in single-cell and high-throughput sequencing are unlocking new biological insights, yet their promise depends on rigorous workflows, interoperable analytics, and reliable reagent and service ecosystems. Operational resilience-spanning diversified sourcing, clear vendor support, and validated protocols-has become as important as technical capability for institutions seeking sustained productivity.

Looking ahead, stakeholders that align investments across consumables, instruments, and analytics while maintaining a focus on reproducibility and regulatory readiness will be best positioned to translate discovery into impact. Collaboration between manufacturers, service providers, and end users will accelerate validation pathways and lower barriers to clinical adoption. Ultimately, the most successful organizations will be those that treat transcriptomics not as a single technology choice but as a systems-level capability that integrates laboratory practice, computational rigor, and supply-chain discipline to deliver reliable, actionable biological insights.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. RNA Analysis/Transcriptomics Market, by Product

  • 8.1. Consumables & Reagents
  • 8.2. Instruments
  • 8.3. Software & Services

9. RNA Analysis/Transcriptomics Market, by Technology

  • 9.1. Digital PCR
  • 9.2. Microarray
  • 9.3. Next Generation Sequencing
    • 9.3.1. Bulk Transcriptomics
    • 9.3.2. Single Cell Transcriptomics
      • 9.3.2.1. Droplet Based
      • 9.3.2.2. Microfluidics Based
  • 9.4. Real Time PCR

10. RNA Analysis/Transcriptomics Market, by Application

  • 10.1. Cancer Research
  • 10.2. Drug Discovery
  • 10.3. Genetic Testing
    • 10.3.1. Carrier Screening
    • 10.3.2. Disease Diagnostics
    • 10.3.3. Prenatal & Newborn Testing
  • 10.4. Infectious Disease Research
  • 10.5. Plant Research

11. RNA Analysis/Transcriptomics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. RNA Analysis/Transcriptomics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. RNA Analysis/Transcriptomics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States RNA Analysis/Transcriptomics Market

15. China RNA Analysis/Transcriptomics Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. 10x Genomics, Inc.
  • 16.6. Agilent Technologies, Inc.
  • 16.7. Bio-Rad Laboratories, Inc.
  • 16.8. Danaher Corporation
  • 16.9. Illumina, Inc.
  • 16.10. Oxford Nanopore Technologies Ltd.
  • 16.11. Pacific Biosciences of California, Inc.
  • 16.12. QIAGEN N.V.
  • 16.13. Roche Diagnostics International AG
  • 16.14. Takara Bio Inc.
  • 16.15. Thermo Fisher Scientific Inc.
  • 16.16. Zymo Research Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CONSUMABLES & REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY BULK TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DROPLET BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY MICROFLUIDICS BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REAL TIME PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CANCER RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY CARRIER SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY DISEASE DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRENATAL & NEWBORN TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY INFECTIOUS DISEASE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PLANT RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 130. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 132. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 134. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 135. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. GCC RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 151. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 155. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 156. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 157. G7 RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 158. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 160. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 162. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 163. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. NATO RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY SINGLE CELL TRANSCRIPTOMICS, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA RNA ANALYSIS/TRANSCRIPTOMICS MARKET SIZE, BY GENETIC TESTING, 2018-2032 (USD MILLION)